Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8783723 | Reproductive BioMedicine Online | 2018 | 8 Pages |
Abstract
Ulipristal acetate (UPA), a selective progesterone receptor modulator (SPRM), offers new therapeutic options for the clinical management of large uterine fibroids associated with heavy menstrual bleeding or with other moderate or severe symptoms (bulk symptoms, pelvic pain, decreased quality of life). SPRM are synthetic compounds that exert an agonist or antagonist effect on target tissues by their binding to progesterone receptors. UPA reduces fibroid size, controls bleeding in a high percentage of women and significantly improves quality of life. The present review aims to provide insights into UPA indications and its mechanism of action.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Jacques Donnez, Guillaume E. Courtoy, Olivier Donnez, Marie-Madeleine Dolmans,